We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
- Authors
Laheru, Daniel; Shah, Preeti; Rajeshkumar, N V; McAllister, Florencia; Taylor, Gretchen; Goldsweig, Howard; Le, Dung T; Donehower, Ross; Jimeno, Antonio; Linden, Sheila; Zhao, Ming; Song, Dongweon; Rudek, Michelle A; Hidalgo, Manuel
- Abstract
S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane. This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metastatic pancreatic adenocarcinoma (PDA).
- Publication
Investigational new drugs, 2012, Vol 30, Issue 6, p2391
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-012-9818-6